New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etonogestrel 68mg;  ; etonogestrel 68mg - subcutaneous implant - 68 mg - active: etonogestrel 68mg   excipient: barium sulfate ethylenevinylacetate copolymer as evatane 10/40 vn4 co polymer   active: etonogestrel 68mg excipient: barium sulfate ethylenevinylacetate copolymer   magnesium stearate - contraception (removed and replaced every three years to ensure continued contraceptive efficacy).

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etonogestrel -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

organon belgium bv-srl - etonogestrel 68 mg - implant - 68 mg - etonogestrel 68 mg - etonogestrel

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - etonogestrel 68mg - subcutaneous implant - 68 mg - active: etonogestrel 68mg

United States - English - NLM (National Library of Medicine)

organon usa inc. - etonogestrel (unii: 304gth6rnh) (etonogestrel - unii:304gth6rnh) - etonogestrel 68 mg - implanon® is indicated for use by women to prevent pregnancy. implanon should not be used in women who have - known or suspected pregnancy - current or past history of thrombosis or thromboembolic disorders - liver tumors, benign or malignant, or active liver disease - undiagnosed abnormal genital bleeding - known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past - allergic reaction to any of the components of implanon [see adverse reactions (6)] risk summary implanon is contraindicated during pregnancy because there is no need for pregnancy prevention in a woman who is already pregnant [see contraindications (4)] . epidemiologic studies and meta-analyses have not shown an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following maternal exposure to low dose chcs prior to conception or during early pregnancy. no adverse development outcomes were observed in pregnant rats

Malta - English - Malta Medicines Authority

n.v. organon kloosterstraat 6, nl-5349 ab oss, netherlands - etonogestrel - implant - etonogestrel 68 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etonogestrel, quantity: 68 mg - implant - excipient ingredients: magnesium stearate; barium sulfate; vinyl acetate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; isododecane; ethylene/vinyl acetate copolymer - contraception (removed and replaced every three years to ensure continued contraceptive efficacy)

United States - English - NLM (National Library of Medicine)

organon usa inc. - etonogestrel (unii: 304gth6rnh) (etonogestrel - unii:304gth6rnh) - etonogestrel 68 mg - nexplanon® is indicated for use by women to prevent pregnancy. nexplanon should not be used in women who have - known or suspected pregnancy - current or past history of thrombosis or thromboembolic disorders - liver tumors, benign or malignant, or active liver disease - undiagnosed abnormal genital bleeding - known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past - allergic reaction to any of the components of nexplanon [see adverse reactions (6)] risk summary nexplanon is contraindicated during pregnancy because there is no need for pregnancy prevention in a woman who is already pregnant [see contraindications (4)] . epidemiologic studies and meta-analyses have not shown an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following maternal exposure to low dose chcs prior to conception or during early pregnancy. no adverse development outcomes were observed in pregnant rats a

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - etonogestrel - prolonged-release subcutaneous implant - 68mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - etonogestrel - prolonged-release subcutaneous implant - 68mg